[²¹²Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors

• Main Authors: Dylan Chapeau (Author), Sofia Koustoulidou (Author), Maryana Handula (Author), Savanne Beekman (Author), Corrina de Ridder (Author), Debra Stuurman (Author), Erik de Blois (Author), Yulia Buchatskaya (Author), Karlijn van der Schilden (Author), Marion de Jong (Author), Mark W. Konijnenberg (Author), Yann Seimbille (Author)
• Format: Book
• Published: MDPI AG, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 (²¹²Pb) represents a promising avenu...